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Abstract 
Background: The objective of this analysis was to determine the value (incremental cost/increment benefit) of a 
brain LITT system versus employing current surgical options recommended by NCCN guidelines, specifically open 
resection (i.e. craniotomy) methods or biopsy (collectively termed CURRENT TREATMENTS) in patients where maximal 
safe resection may not be feasible. As has been demonstrated in the literature, extent of resection/ablation with mini-
mal complications are independently related to overall survival.
Methods: A cost effectiveness analysis from a societal perspective was employed using TreeAge Pro 2014 software. 
Direct costs (using national average Medicare reimbursement amounts), outcomes (overall survival), and value 
[defined as increment cost/incremental survival—evaluated as cost/life year gained (LYG)] were evaluated. Sensitivity 
analysis was also performed to determine which variables had the largest effect on incremental costs and outcomes.
Results: In the base case, the overall survival was improved with brain LITT versus CURRENT TREATMENTS by 
3.07 months at an additional cost of $7508 (or $29,340/LYG). This amount was significantly less than the current 
international threshold value for $32,575/LYG and considerably less than the US threshold value of $50,000/LYG. This 
incremental cost may also qualify under NICE criteria for end of life therapies. In sensitivity analysis: As percent local 
recurrence GBM increased; cost of DRG25/26 increased; percent GTR increased; and gliadel use increased—the value 
of brain LITT improved. Additionally, in those patients where a biopsy is the only option, brain LITT extended life by 
7 months.
Conclusions: Brain LITT should be considered a viable option for treatment of high grade gliomas as it improves 
survival at a cost which appears to be of good value to society. This incremental cost is less than the international and 
US thresholds for good value.
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Background
According the Central Brain Tumor Registry of the US 
(CBTRUS), there are over 138,000 people in the US living 
with primary brain and central nervous system malignant 
tumors primary in the United States [1]. The incidence of 
primary malignant brain tumors is expected to be over 
23,000 in 2015 [1]. Of these types of tumors, >50 % [2–4] 
(approximately 11,500) are classified as being at high risk 
[for complications] for resection. This is mainly due to the 
grade of tumor and these tumors residing in or near areas 
of eloquence or being deep seated in nature (e.g. tumor 
residing in the brain stem [also referred to as complex 
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anatomy]). Extent of resection (EOR) with the aim of 
maximal cytoreduction of the tumor is strongly corre-
lated with outcomes (i.e. survival and function as classi-
fied under the Karnofsky performance scale) [5] and the 
effectiveness of other treatment modalities such as radia-
tion or chemotherapy [6, 7]. One of the main issues with 
tumors that are in or near areas of eloquence or, that are 
deep seated in nature, is an inability for neurosurgeons to 
adequately resect the tumor without causing longer term 
neurological complications from surgery (i.e. open resec-
tion or biopsy or CURRENT TREATMENTS). Craniot-
omy procedures that have been performed on high-grade 
gliomas in or near areas of eloquence have historically 
resulted in neurological complications (i.e. functional 
and/or cognitive deficits on a neurological basis) that are 
permanent in nature and result in suboptimal resection. 
These major complication rates range from 4.5 to 13  % 
in large cohorts of patients [8–17] and also result in sub-
optimal EOR of 78–<95  % [5, 8, 12–14]. Further, these 
acquired neurological complications resulting from sur-
gery result in decreased median survival rates [18]. While 
the National Comprehensive Cancer Network (NCCN) 
includes the use of craniotomy or biopsy [19] [referred to 
as CURRENT TREATMENTS moving forward] for sub-
total resection in its treatment algorithms for primary or 
recurrent glioblastoma (where maximal resection is not 
safe or feasible), it does not make evidentiary or consen-
sus recommendations on their use [19].
Recently new MRI guided laser interstitial thermal 
therapy (LITT) systems for ablating neurological soft-
tissue have been FDA cleared and; covered and paid for 
by Medicare (via a new technology add on payment) in 
treating primary and recurrent gliomas [20, 21]. These 
technologies, have been reported on extensively in the 
literature, including in two systematic reviews [22, 23]. 
These technologies apply focused laser energy which 
a surgeon uses to ablate tissue such as tumors from the 
inside of the brain (using a bur or twist drill hole for brain 
access). Real time MRI thermometry is also used so that 
surrounding healthy tissue damage can be minimized. 
These systems allow surgeons to selectively ablate tumors 
and lesions in the brain that may have been previously 
deemed inoperable, difficult to access, or unsafe to resect 
based on their location in or near areas of eloquence.
In examining the use of brain LITT in the peer review 
literature in the subset of patients whose high grade 
glioma resides in or near areas of eloquence or; that are 
deep seated in nature, it was found that the major com-
plication rates directly resulting from the brain LITT sur-
gery were in the 0–6 % range; average of 2.7 % (Table 1), 
which is lower than 4.5–13  % seen in CURRENT 
TREATMENTS (Table 2). (Note: The analysis as found in 
Table 1 shows all types of brain LITT used in high-grade 
gliomas located in areas of eloquence over the years, with 
and without the use of MRI guidance.) As well, it has 
been found that physicians who are experienced in using 
brain LITT technology in complex anatomy experience 
an EOR approaching 98  % [24] and that those who are 
treated with brain LITT experience a length of stay (LOS) 
that averages 3  days [24]. This is in contrast to patients 
who are treated with open craniotomy with ICD9CM 
Diagnosis codes 191.0–191.8, whose LOS average 
6.55 ± 1.77 days under diagnostic related groups [DRG] 
25–27 (craniotomy with and without comorbidity/com-
plication) [25].
In establishing the value of a new treatment, the new 
option is compared to the weighted costs and out-
comes of the combined existing treatments [CURRENT 
TREATMENTS] for the same patient population. In the 
United States cost effectiveness ratios of <$50,000/life 
year gained [LYG] are considered attractive [26]. From 
an international perspective, <30,000€ (or $32,575 in 
current US dollars)/LYG [or at $2714/month survival 
gained] is considered a good value [27].
It is with these facts in mind that an analysis was 
undertaken to evaluate the direct costs and overall sur-
vival of treating complex high-grade gliomas utilizing 
either brain LITT or CURRENT TREATMENTS (per 
the NCCN CNS practice guidelines [19]). The costs and 
overall survival (OS) were evaluated via a cost effective-
ness analysis (including sensitivity analysis) as described 
below. The hypothesis being tested is that the use of brain 
LITT in these types of patients would be considered cost 
effective (i.e. of value) at a willingness to pay (WTP of 
<$32,575/LYG or incremental cost $2714/incremental 
month of survival) in patients with complex brain anat-
omy (which included brain tumors in or near areas of 
eloquence or; in deep seated tumors which are difficult to 
access via surgery). This analysis examines this incremen-
tal cost/incremental survival benefit (termed ICER).
Methods
A decision tree was developed to evaluate the cost-effec-
tiveness of using brain LITT versus CURRENT TREAT-
MENTS (collectively craniotomy  ±  gliadel wafer, plus 
biopsy) in patients with complex anatomy. Additionally, 
brain LITT was compared to the separate procedures 
of craniotomy without gliadel wafer, craniotomy w/glia-
del wafer, and biopsy only (which collectively make up 
CURRENT TREATMENTS) in these patients. The soft-
ware program used was TreeAge Pro 2014, a decision 
tree/Markov modeling software program widely used in 
health care for evaluating cost effectiveness.
The decision tree evaluated the initial procedure 
and the resultant outcome (i.e. gross total resection 
[GTR]; subtotal resection [STR])—using probabilities as 
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identified in the peer-reviewed literature and as found in 
Tables 3, 4. Further it was assumed that patients received 
adjunct care (e.g. chemotherapy, external beam radiation 
therapy (EBRT) where appropriate based on the EOR 
and; as per the NCCN guidelines [19], and evidence-
based recommendations [28, 29]. Patients were followed 
through the treatment decision tree until they died. Gross 
total resection was defined as an EOR of ≥98  % and a 
subtotal resection (STR) was classified as less than <98 %. 
The outcome of the surgery was also evaluated based on 
the resultant Karnofsky performance scale (KPS). The 
progression free survival (PFS) of the initial procedure 
was based off of the EOR as found in the literature and 
as outlined in Tables  3, 4 below. Progression free sur-
vival times and KPS were determinants of when/whether 
a second procedure was performed. Further, patients 
whose recurring tumor was local in nature were treated 
with a second surgery and follow on adjunctive treat-
ment where appropriate, based on the clinical guidelines 
(e.g. ±  gliadel wafer [based on evidence from databases 
and the literature this occurred 10–30 % of the time] [30, 
31], systemic chemotherapy). Patients whose tumor was 
diffuse in nature were treated with either palliative care 
or EBRT (external beam radiation therapy)  ±  chemo-
therapy, depending upon their KPS. As well, patients 
whose resultant KPS was <70 after surgery were treated 
with palliative care for the remainder of their lives. Thus 
as an example: if a primary procedure under brain LITT 
resulted in a GTR and the outcome was favorable (e.g. 
KPS >70 post procedure) (note: the primary procedure 
would include adjunctive EBRT plus chemotherapy)—
the PFS time as identified in the literature was used for 
determining a second procedure. If the tumor recurred 
locally, a second brain LITT procedure was performed. If 
the outcome of the second procedure was favorable (e.g. 
KPS >70) the patient was treated with follow on therapy 
(e.g. chemotherapy) and then followed for the remain-
der of their life. The decision tree for treatment followed 
the clinical guidelines as found in the NCCN CNS clini-
cal practice guidelines [19]. Neurocognitive complication 
rates as identified above were also used in the model and 
affected treatment options and downstream costs such as 
rehabilitation post procedure. 
Direct societal costs used in the model were derived 
from 2015 Medicare national averages for surgery 
(including hospital in-patient and physician services ren-
dered during the inpatient stay) and follow on care (e.g. 
radiation therapy, chemotherapy, rehabilitation [for a 
complication] or palliative/home hospice care). These 
costs can be found in Tables  3, 4. Table  5 shows what 
the overall costs for an acute inpatient stay for tumor 
removal and; is be based on a weighted average use and 
cost for DRG’s 25–26 (using 2012 Medicare data on the 
incidence of each procedure and 2015 National aver-
age reimbursement rates for Medicare) [32] plus the 
physician services rendered for each treatment type 
Table 1 Studies examining the use of LITT with high grade gliomas in areas of eloquence
KPS Karnofsky performance scale, rGBM recurrent glioblastoma multiforme, GBM  glioblastoma multiforme
a Major complications = Neurocognitive complications extending >3 months post surgery




Tumor type Length of stay Extent  
resection
KPS (pre/post) Major  
complications 
(%)a
Sakai [42] 3 Denovo glioma N/A 100 % Two patients had a 
90 and 100 KPS pre-
surgery; other not 
mentioned
0
Reimer [43] 4 Recurrent glioma Shorter with LITT vs. 
craniotomy
N/A N/A 0
Schwarzmaier [40] 16 rGBM Shorter with LITT vs. 
craniotomy
N/A N/A 0
Carpentier [44] 4 rGBM Patients discharged  
the next day
100 % Unchanged pre and 
post-surgery
0
Jethwa [45] 3 GBM Median 1 day 100 % N/A 0
Sloan [46] 8 rGBM 3.75 ± 1.83 days 
(mean ± SD)
78 ± 12 % Pre-surgery 85; post 83 0
Schroeder [47] 2 Anaplastic  
astrocytoma
N/A 92.8 % (mean) [range 
77.7–100 %]
Pre-surgery 80 0
Mohammadi [24] 35 rGBM = 19
Glioma/GBM = 16
Median 3 days (range 
1–29 days)
98.2 % (median) Pre-surgery 80 6
Totals 75 (2/75 = 2.7)
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(brain LITT, craniotomy, biopsy). Table 5 also shows the 
national average weighted costs for DRG 23 (when cra-
niotomy with gliadel wafer placement was performed). 
Effectiveness was evaluated as overall survival (OS) of the 
patient. These values were derived from the literature and 
based on the outcome of the first and second (if indicated 
and based on the clinical guidelines) surgical procedures. 
Costs and OS were discounted at 3  % annually—which 
is the most commonly used discount rate for medical 
therapies [33]. Costs and OS used normal distributions 
along with confidence intervals and standard deviations 
for probabilistic analysis. Cost effectiveness analysis 
(incremental cost of using brain LITT plus other inter-
ventions (includes such interventions such as: adjunc-
tive therapies, treatment for complications, hospice care) 
over the life of the patient/LYG; termed incremental cost 
effectiveness ratio (ICER) moving forward) was analyzed 
to determine whether the incremental cost/incremental 
survival was under internationally accepted cost/LYG 
thresholds. Sensitivity threshold analysis was performed 
Table 4 Distributions used in the model
Type Name Description Param 1 Param 2 Param 3
Triangular Percent_major_complications_surgery Percent of patients experiencing a major complication 
from surgergy
0.045 0.09 0.13
Triangular Percent_major_complications_LITT Percent of major complications resulting from LITT 
procedure
0.0 0.027 0.06
Uniform Percent_GTR_biopsy Percentage of patients who have a GTR with biopsy 0.0 0.45
Uniform Percent_major_complications_biopsy Percent of major complications resulting from stereotactic 
biopsy
0.031 0.064
Uniform Percent_unresectable_rGBM_surgery Percent of recurrent GBMS that are unresectable with 
open craniotomy surgery
0.23 0.38
Uniform Percent_open_resection_total Percent of eloquent areas of brain where a total resection 
was achieveable
0 0.23
Uniform OS_EOR_biopsy Overall survival in months with biopsy based on an 
assumed extent of resection of <=70 %
4.85 12
Triangular OS_EOR_STR Overall survival in months with Subtotal Resection biopsy 
or craniotomy based on an assumed extent of resection 
of >=85 %
9.7 10.9 12.2
Triangular OS_EOR_GTR Overall survival in months with Subtotal Resection biopsy 
or craniotomy based on an assumed extent of resection 
of >=98 %
11.4 13.1 14.6
Uniform Added_Survival_SRS Additional overall survival in months with use of SRS in 
patients who have a KPS >=70
7.5 8.5
Uniform OS_recurrent_Diffuse_GBM Overall survival of recurrent diffuse GBM 6 7
Normal PFS_LITT_GTR Progession free survival using LITT—assuming GTR 12.2 13.6
Normal PFS_LITT_STR Progression free survival using LITT with subtotal resection 7.4 7
Normal PFS_biopsy_GTR Progession free survival using biopsy with GTR 12.2 13.6
Normal PFS_biopsy Progression free survival using biopsy with inadequate 
resection
4.8 5.2
Normal PFS_surgery_GTR Progression free survival with surgery and GTR 12.2 13.6
Normal PFS_surgery_STR Progression free survival with surgery with STR 7.4 7
Normal LOS_surgery_GBM Average LOS and std dev for GBM procedures under DGR 
26; 2012 data
6.55 1.77
Uniform Timing_follow_on_chemo_TMZ Amount of time in days of follow on TMZ chemotherapy 180 360
Normal Incremental_survival Incremental overall survival with implanting a carmustine 
wafer versus not
3.3 4.467
Triangular Percent_neuro_comps_0_to_3_mths_surgery Percent of neurological complications (motor and 
cognitive lasting 0–3 months requiring rehabilitation; 
independent of major complications =>4 months
0.06 0.068 0.153
Uniform Percent_neuro_comps_0_to_3_mths_LITT Percent of neurological complicaitons (motor and 
cognitive lasting 0–3 months requiring rehabilitation; 
independent of major complications =>4 months
0 0.02
Uniform Percent_Gliadel_wafer_implantations Percent of time a Gliadel wafer implanted in a patient for 
treating brain cancer
0.1 0.33
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to determine which variables had the greatest effect on 
the ICER. Lastly, Monte Carlo simulation (expected value 
for 10,000 simulated trials) was also run. These analyses 
were performed using TreeAge Pro 2014 (TreeAge Soft-
ware, Inc., Williamstown, MA). Figure 1 depicts a section 
of the decision tree related to treatment with brain LITT 
for gross total resection (≥98 % tumor ablated).
Results and discussion
Table  6 compares the overall costs and survival in 
employing either brain LITT or CURRENT TREAT-
MENTS (again which is comprised of either open resec-
tion ± gliadel wafer or biopsy) in cases where high-grade 
gliomas reside in or near eloquent areas of the brain or 
are deep seated. As can be seen in the base case, the addi-
tional costs (over the lifetime of the patient) with LITT 
vs. CURRENT TREATMENTS is $7508 and the over-
all improved survival with brain LITT vs. CURRENT 
TREATMENTS is 3.07  months. More specifically, as it 
relates to cost effectiveness, for every month in survival 
gained, it would cost an additional $2445 in using brain 
LITT versus CURRENT TREATMENTS. This translates 
into an incremental cost per LYG of $29,340 when using 
brain LITT. If one examines brain LITT compared to 
each option separately (that is the procedures contained 
within CURRENT TREATMENTS) the increment costs 
per LYG are: $8458/LYG compared to craniotomy (which 
consisted of a combination of craniotomy with and with-
out gliadel wafer) and $48,552/LYG when compared to 
biopsy (Table  7). Table  8 shows similar findings with a 
Monte Carlo simulation.
Sensitivity analysis performed via a tornado plot (Fig. 2) 
showed that with a willingness to pay (WTP) of $2714/
month of survival (same as the international threshold 
of $32,572/LYG) the following variables had the great-
est effect on the model: Percent local recurrence of the 
GBM (Fig.  3)—with the higher the occurrence of local 
GBM recurrence (vs. diffuse recurrence) the more likely 
brain LITT was to be cost effective; the higher the cost 
of a craniotomy procedure (i.e. DRG 25/26)—the more 
cost effective brain LITT became (Fig. 4); the higher the 
likelihood (or probability) of a subtotal resection (versus 
GTR); the less cost effective brain LITT became (Fig. 5) 
and; the higher the probability of use of gliadel wafers, 
the less cost effective brain LITT became (Fig. 6) (Note 
that with Fig. 6, the higher use of gliadel wafers resulted 
in a negative incremental cost/negative OS (result-
ing in a positive ICER for brain LITT—which in reality 
shows that the ICER is reflective of the additional cost 
and additional survival with gliadel versus brain LITT). 
What Fig. 7 further clarifies is that brain LITT dominates 
craniotomy plus carmustine use in that it is both less 
expensive and produces improved overall survival (Note: 
Strategies that dominate are depicted in the lower right 
hand corner of cost effectiveness graphs and; strategies 
that are dominated are shown in the upper left hand cor-
ner of the same graph). Lastly Fig. 7 shows that at a WTP 
of $2714/additional month of survival, the favored strat-
egy is brain LITT (as the WTP intersects with the brain 
LITT data point).     
Table 9 shows the likelihoods of a “good performance 
status (Karnofsky score ≥70) post surgery with and 
Table 5 Costs of care based on Medicare reimbursement to the hospital and physician for brain LITT, craniotomy w/car-
mustine, craniotomy w/o carmustine, or biopsy inpatient procedures—tumor resection
LOS length of stay in days, DRG diagnostic related group, CPT current procedural terminology








DRG 25-26—craniotomy $22,291 – $22,291 $22,291
DRG 23—craniotomy with chemo implant – $31,090 – –
CPT 00210—anesthesia $1010 $1010 $1010 $1010
CPT 99144/5—physician observation of sedation $320 $320 $320 $320
CPT 61510—craniotomy – $2225 $2225 –
CPT 61517 – $94 – –
CPT 61751 – $1405
CPT 61781 $235 – –
CPT 61798 $1410 – –
CPT 61799 $975 – – –
CPT 61800 $165 – $165
CPT 99222 $138 $138 $138 $138
CPT 99233 @ $105/day $315 $840 $840 $630
Total $26,859 $35,717 $26,824 $25,959
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without GTR and; the costs and OS survival associated 
with each (as calculated by TreeAge 2014). As mentioned 
above, GTR is defined as an EOR of ≥98 % (with subtotal 
resection <98 % EOR). What Table 9 also shows is that for 
the “ideal outcome” for brain cancer surgery (i.e. a GTR 
with good performance status): this occurs 36  % of the 
time in brain LITT surgery (with an OS of 22.58 months); 
9 % with craniotomy without gliadel wafer (with an OS of 
21.75 months) and; 8 % of the time in craniotomy w/glia-
del wafer (with an OS of 25.05 months). (NOTE: Biopsy 
was not factored in this analysis since the result is <98 % 
EOR). In other words there appears to be 4× higher like-
lihood of having a good functional outcome along with 
GTR using brain LITT than with the other options avail-
able (Fig. 8).
Based on current US (<$50,000/LYG) and International 
(<30,000€/LYG or $32,575/LYG) threshold values for 
value, brain LITT should be considered to be “of value” 
Fig. 1 Brain LITT arm of decision tree examining costs/outcomes of patients with a gross total resection
Table 6 Base case comparing LITT versus  OTHER PROCE-
DURE on the outcomes of costs and overall survival
Treatment Cost Overall survival in months
Brain LITT $89,839 19.04
OTHER TREATMENTS $82,331 15.97
Table 7 Incremental cost/LYG
Therapy Cost Overall survival (OS) 
[months]
Incremental cost/increment 





Biopsy $63,458 12.52 $4046/mth $48,552/LYG
Craniotomy (includes ± carmustine wafer) $87,654 16.94 $795/mth $8458/LYG
OTHER TREATMENTS-combines craniotomy plus biopsy) $82,331 15.97 $2445/mth $29,340/LYG
Brain LITT $89,839 19.04 N/A N/A
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as; its incremental cost/LYG gained (compared to CUR-
RENT TREATMENTS) of $29,340/LYG is less than the 
thresholds accepted as good value [26, 27]. If one were 
to examine a comparison in resection of the tumor (i.e. 
brain LITT compared to craniotomy—the most reason-
able side by side comparison to make), the value is sig-
nificantly improved at $8458/LYG; again an amount 
considered to be of good value and; well below accepted 
thresholds internationally and in the US. As well, com-
pared specifically to other cancer therapies, brain LITT 
represents a better value in money spent in extending 
survival [27, 34]. Additionally, these findings have impor-
tant implications for providers, payers, and patients. For 
providers, the use of brain LITT may extend the overall 
survival in these types of patients and, at a stable or pos-
sibly a better KPS (based on reduced neurological com-
plication rates which in turn would lower KPS scores). 
Secondly, for payers, this represents good value based 
on accepted value thresholds. For patients, it appears 
that OS may be improved based on improved EOR; with 
less of a likelihood of ending up with surgical complica-
tions—which in turn can compromise cognitive and 
physical functioning.
There are currently no evidence based recommenda-
tions for resecting high-grade gliomas when maximal 
safe resection is not feasible as per the NCCN guidelines 
[19]. While both subtotal resection and biopsy are men-
tioned in the NCCN clinical practice guidelines as surgi-
cal options, they have significant limitations. Both biopsy 
and open resection generally result in no or suboptimal 
resection (<98 %) [5, 8, 12–14], respectively, with a high 
rate of surgically related complications in the resection 
group (4.5–13 % [8, 10–14]) when used in these types of 
patients. As well, patients who had perioperative com-
plications with open resection are less likely to receive 
radiotherapy or chemotherapy—thus affecting their sur-
vivability [27].
The ideal outcome in these types of patients is to 
achieve GTR without postoperative neurologic compli-
cations as; cytoreduction (EOR) without complications 
plays a very important role in overall survival [12, 27]. 
Recent advances in less invasive brain LITT (under real 
time MRI guidance) have produced promising results, 
with lower complication rates (Table  1). What this 
decision model demonstrates is that by improving the 
EOR and lowering procedure related major complica-
tions via brain LITT, the overall costs for treating these 
Table 8 Monte Carlo simulation (run 10,000 times) com-
paring LITT versus  OTHER PROCEDURE on  the outcomes 
of costs and overall survival
Treatment Cost Overall survival in months
Brain LITT $89,785 ± $15,885 19.12 ± 3.51
OTHER TREATMENTS $82,042 ± $22,070 15.95 ± 4.04
Fig. 2 Tornado sensitivity analysis—ICER measured as incremental cost per incremental month survival: LITT versus CURRENT TREATMENTS
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type of patients over their remaining lives increase 
minimally (with the additional costs being incurred 
post procedure via adjunct therapies used to improve 
OS—based mainly on the ability of clinicians to more 
frequently/effectively use adjunct therapies with brain 
LITT). These adjunct therapies can be used due to a 
Fig. 3 One way sensitivity analysis—ICER local recurrence GBM
Fig. 4 One way sensitivity analysis—ICER DRG 25/26
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greater volume of tumor removal with lower compli-
cation rates [6, 7, 35]. The main reason for this is the 
ability of the brain laser under MRI guidance to selec-
tively ablate cancerous lesions in and around areas of 
eloquence with less perioperative complications than 
CURRENT TREATMENTSs. Perioperative compli-
cations (including surgically acquired motor, sen-
sory and cognitive deficits) have been found to be an 
Fig. 5 One way sensitivity analysis—ICER percent subtotal resection
Fig. 6 One way sensitivity analysis—ICER percent gliadel wafer use
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independent risk factor associated with overall sur-
vival [35]. An added benefit of the use of brain LITT is 
a decreased length of hospital stay which in turn also 
reduces overall costs (i.e. lower physician related costs 
for inpatient care) [20]. Additionally, a potential benefit 
of brain LITT versus open resection may be the ability 
of patients to ambulate more quickly, potentially reduc-
ing the incidence of venous thromboembolism (VTE), 
which can be high in brain cancer and whose risk is 
further increased post craniotomy [36].
The use of gliadel wafers in high grade gliomas is con-
troversial [37] and their use appears to be practiced 
judiciously in the US despite being recommended by the 
NCCN guidelines [19]. The model attempted to account 
for this and used ranges found in the literature and in 
publicly available datasets [30, 31].
While the incremental cost/LYG using brain LITT 
versus biopsy only ($48,552/LYG) exceeds the interna-
tional threshold of $32,575/LYG, it is lower than the US 
threshold of <$50,000/LYG and thus would be consid-
ered acceptable in the US. Additionally, incremental cost 
effectiveness ratio (ICER) threshold values established by 
countries such as the UK (via NICE) for end of life thera-
pies (with the criteria for consideration under this being: 
Fig. 7 Cost-effectiveness analysis—LITT dominance
Table 9 Costs and  overall survival based on  good performance status (Karnofsky ≥70) and  extent of  resection/abla-
tion—by procedure performed—percent likelihood of event occurring
Procedure Cost Overall Survival (months) % occurrence
Gross total resection/ablation (≥98 % EOR) and good performance status (Karnofsky ≥70)
 Brain LITT $91,356 22.58 36 %
 Craniotomy w/o carmustine wafer $89,698 21.75 9 %
 Craniotomy w/carmustine wafer $99,013 25.05 8 %
Subtotal resection (STR)/ablation (<98 %) and good performance status (Karnofsky ≥70)
 Brain LITT $89,721 17.46 61 %
 Craniotomy w/o carmustine wafer $86,493 16.95 49 % (of all OTHER treatments performed)
 Craniotomy w/carmustine wafer $99,679 20.25 15 % (of all OTHER treatments performed)
 Biopsy $62,959 12.72 21 % (of all OTHER treatments performed)
Page 15 of 17Voigt and Barnett  Cost Eff Resour Alloc  (2016) 14:6 
life extension of >3  months, small patient population, 
and prognosis of <24 months) may be more flexible than 
the threshold set of £20,000–£30,000 for all other thera-
pies/diagnostics/interventions [38]. Thus it may meet the 
UK threshold. More importantly however, brain LITT 
should be compared to CURRENT TREATMENTSS as; 
brain LITT would take place of the other therapeutic 
options (craniotomy  ±  gliadel and biopsy) listed under 
CURRENT TREATMENTS in this patient population. 
Lastly in this analysis, incremental cost/LYG is likely the 
more appropriate analysis than incremental cost/quality 
adjusted life year (QALY) for this condition as; mortality 
effects are likely to have a more significant impact relative 
to Quality of Life (QoL analysis); along with the fact that 
time and resource use are especially constrained in this 
condition. In these type of circumstances, analysts typi-
cally have chosen LYG versus QALY [39].
As it relates to limitations of this analysis the following 
should be noted:
It was not possible to examine KPS as an outcome 
based on the small number of patients where this was 
evaluated. However, and as mentioned above, post-
surgery KPS is reflective of neurological complications 
resulting from surgery. Thus in aggregate, KPS would 
likely have been higher in the brain LITT arm of the deci-
sion tree.
Early studies with brain LITT demonstrate a learning 
curve and as clinicians gain more experience, it appears 
that the outcomes improve [24, 40]. Additionally, the out-
comes/data used for “CURRENT TREATMENTS (open 
resection or biopsy)” are well established. It is possible 
that as time progresses and brain LITT becomes better 
established (especially for use in these types of patients) 
that the overall outcomes would improve for brain LITT.
Complications resulting in repeat surgery from chemo-
therapy implants (e.g. gliadel wafer); craniotomy, brain 
LITT and biopsy were not evaluated for cost and their 
effect on overall survival. These complications resulted in 
approximately a 3 % repeat surgery rate and are highest 
in the gliadel wafer group [29, 37].
It was assumed based on level II evidence and in the 
literature reviewed that gliadel wafers were implanted 
in approximately 10–33 % of patients in the open resec-
tion arm of CURRENT TREATMENTS [28, 29]. This 
may not be the case in all situations. If not used in all 
instances, the overall costs for the open resection arm (of 
CURRENT TREATMENTS’s performed) would be less 
(however to the detriment of overall survival). It was also 
assumed in the decision tree model that the application 
of a chemotherapy implant conferred a 3.3 month incre-
ment in overall survival [29].
Fluorescent guided surgery using 5-ALA may not 
be entirely accurate in identifying complete resection 
and is not FDA-approved in the United States [41]. 
Some of the studies where EOR was evaluated for cra-
niotomy used this technology [3, 8]. Thus the EOR for 
Fig. 8 Cost effectiveness analysis—Willingness to Pay
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craniotomy may have been overestimated—which in 
turn affected the overall survival numbers in this arm of 
the decision tree.
Extent of ablation (EOA) from the recent Mohammadi 
study was used for the brain LITT arm of the trial as a 
proxy for EOR [24]. In this study the EOA was defined 
by thermal damage threshold (TDT) lines. Since there 
is no data in the literature regarding the EOA of ther-
mal damage by brain LITT, it was assumed that the TDT 
lines defined EOR and, because of this, the 98  % figure 
was used for EOR in the brain LITT arm of the decision 
tree model for both PFS and OS. In a prior review of the 
literature, EOA and EOR, were considered equivalent for 
PFS [24]. Lastly, since OS had not been followed out long 
enough for brain LITT, it was also assumed that the 98 % 
value for EOA with brain LITT assumed a similar OS tra-
jectory as craniotomy.
Conclusions
The use of brain LITT under MRI guidance in complex 
craniotomies where high-grade gliomas reside in or 
near areas of eloquence (or where these types of tumors 
are deep seated) appears to be cost effective—provid-
ing value based on it being lower than “value” thresholds 
established by policy makers. The implications are that 
brain LITT should be considered a treatment option in 
these types of high-risk patients.
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